Share

cover art for Curve Therapeutics – Addressing challenging drug targets

Optimum Perspectives

Curve Therapeutics – Addressing challenging drug targets

Ep. 21
•

Southampton-based Curve Therapeutics recently raised a hefty £40m in a Series A financing round.

 

In this in-depth podcast, CEO Simon Kerry describes how investors fell in love with Curve’s “Microcycle” based discovery platform, which gives the company “the ability to potentially identify drugs against very difficult, challenging targets”.


He explains how Curve’s platform enables them to spot drugs with a higher chance of working in real-world conditions. He also outlines the firm’s lead programme – which aims to block two cancer targets called Hypoxia Inducible Factors, or “HIFs”, which enable solid tumours to survive in low-oxygen conditions.


Speaking to Optimum’s Stephen Adams, Simon ponders the role of luck in securing investment, both “the kind you deserve because you turn over a lot of stones”, and the more fortuitous variety.

More episodes

View all episodes

  • 28. Kling Biotherapeutics: Using B cell tech to discover new targets and antibodies in cancer

    09:17||Ep. 28
    Great new insights in the Optimum Perspectives' latest podcast edition featuring Stefano Gullà, Chief Scientific Officer at Kling Biotherapeutics, about the growing role of B cell technology in cancer therapy.  

  • 27. DISCO Pharmaceuticals looks to unlock new drugs with “surfaceome” technology

    15:51||Ep. 27
    In this podcast to mark Lung Cancer Awareness Month, Optimum’s Richard Staines speaks to Roman Thomas, CEO and founder of Disco Pharmaceuticals, on breakthroughs that have improved patient outcomes, and the company’s efforts to help develop new therapies with its “surfaceome” technology. 

  • 26. SpliceBio: Celebrating progress in ophthalmology research on World Sight Day

    11:42||Ep. 26
    Optimum’s Richard Staines talks to Feride Sahin, Senior Director of Clinical Development at Splice Bio about the importance of World Sight Day, which takes place this week.

  • 25. Heidelberg Pharma – turning deadly mushroom toxin into cancer medicine

    14:24||Ep. 25
    It’s time to talk about mushrooms! Or rather the deadly toxin amanitin found in the death cap mushroom, which Heidelberg Pharma is using as a cancer drug with the help of a tumour-targeting antibody, find out more in this episode featuring Heidelberg Pharma's CEO, Andreas Pahl.

  • 24. Resolution Therapeutics: pioneering macrophage therapies for liver diseases

    27:55||Ep. 24
    Check out Optimum’s latest podcast episode profiling our client Resolution Therapeutics. Lara Campana, VP of Research Operations outlines the company’s technology based around pro-regenerative macrophages and its potential to treat liver disease.

  • 23. Q&A with Dr Ruth McKernan CBE: Neuroscientist, businesswoman and innovation leader

    21:42||Ep. 23
    Dr Ruth McKernan CBE is the richly deserved winner of the 2024 Mediscience Award for ‘Most Significant Contribution to the Mediscience Sector’. In this episode Optimum’s Eva Haas discusses the highlights of Ruth’s incredible career, the skills needed for success as a company founder and the heartening advancements in treating neurodegenerative diseases such as Alzheimer's in recent years.

  • 22. How AI is revolutionising drug research

    23:39||Ep. 22
    Listen to expert discussion on the role of AI in drug development, featuring Tushar Pandey, CEO and Co-founder of SimBioSys, and Jeremy Skillington, CEO of Poolbeg Pharma.

  • 20. Biotech IPOs make a comeback in 2024

    20:55||Ep. 20
    Listen to the latest insights from Gil Bar-Nahum, Managing Director in the Global Healthcare Investment Banking Group, Jefferies International, on how to succeed in the new wave of biotech IPOs in the Optimum Perspectives podcast.